The Food and Drug Administration (FDA) advises the public against the purchase and use of the counterfeit version of the following product: All healthcare professionals and the general public ...

Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval ...

Cancer treatment drug Pembroria, which has the same active ingredient as Keytruda but is cheaper, has been licensed for ...

CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1 monotherapy biomarker data at SITC 2025 ...

Q3 2025 Earnings Call Transcript November 7, 2025 Operator: Good afternoon, everyone. Thank you for standing by. Welcome to ...

As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its ...

Merck (NYSE:MRK) announced on Thursday that the FDA has granted priority review for two of its marketing applications aimed at expanding the U.S. indications of injectable and intravenous versions of ...

Additional updates from the ongoing Phase 1b/2 trial with muzastotug, previously reported at ASCO 2025, are anticipated in the coming months SAN DIEGO and SUZHOU, China, Oct. 31, 2025 (GLOBE NEWSWIRE) ...

Merck (NYSE:MRK) is set to report its third-quarter earnings on Thursday, October 30, before the market opens. Consensus estimates call for earnings per share of $2.35, up 49.7% year over year, and ...

As Merck looks for growth opportunities ahead of Keytruda’s tumble over the patent cliff, the company’s future now looks a bit brighter in the glow of two late-stage trial wins for cancer drug Welireg ...

Merck & Co. and Eisai previously had high hopes for their Keytruda-Lenvima combination in a liver cancer subtype based on positive progression-free survival data, but now the combo’s promise has once ...